Home
CSTL
CSTL News

Latest Castle Biosciences Inc. (CSTL) News on November 23, 2024

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Zacks

2 days ago

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Business Wire

3 days ago

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

Zacks

4 days ago

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Business Wire

4 days ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

Zacks

5 days ago

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Zacks

9 days ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Zacks

11 days ago

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

11 days ago

Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

15 days ago

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Business Wire

15 days ago

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why

Zacks

16 days ago

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why

Castle boasts melanoma test’s capacity to reduce unnecessary testing

Medical Device Network

16 days ago

Castle boasts melanoma test’s capacity to reduce unnecessary testing

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

Business Wire

16 days ago

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

Business Wire

17 days ago

Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

Castle Biosciences price target raised to $39 from $37 at Baird

TipRanks

17 days ago

Castle Biosciences price target raised to $39 from $37 at Baird

Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

17 days ago

Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations

Castle Biosciences price target raised to $36 from $28 at KeyBanc

TipRanks

17 days ago

Castle Biosciences price target raised to $36 from $28 at KeyBanc

MT Newswires

18 days ago

Castle Biosciences Insider Sold Shares Worth $273,251, According to a Recent SEC Filing

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

18 days ago

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates

Zacks

19 days ago

Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates

Castle Biosciences Reports Third Quarter 2024 Results

Business Wire

19 days ago

Castle Biosciences Reports Third Quarter 2024 Results

Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?

Zacks

22 days ago

Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect

GuruFocus.com

22 days ago

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients

Business Wire

25 days ago

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients

Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

25 days ago

Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Castle Biosciences to Participate in Upcoming Investor Conferences

Business Wire

a month ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going

Zacks

a month ago

Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going

Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?

Zacks

a month ago

Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?

MT Newswires

a month ago

Castle Biosciences Says Data Shows Efficacy of its Skin Cancer Tests

Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors

Business Wire

a month ago

Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors

Business Wire

a month ago

Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential

Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?

Zacks

a month ago

Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?

Castle Biosciences price target raised to $40 from $35 at BTIG

TipRanks

a month ago

Castle Biosciences price target raised to $40 from $35 at BTIG

Castle Biosciences, Inc.'s (NASDAQ:CSTL) Intrinsic Value Is Potentially 95% Above Its Share Price

Simply Wall St.

a month ago

Castle Biosciences, Inc.'s (NASDAQ:CSTL) Intrinsic Value Is Potentially 95% Above Its Share Price

Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?

Zacks

a month ago

Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?

Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024

Business Wire

a month ago

Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024

Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin

Business Wire

a month ago

Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin

Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

a month ago

Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...

New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions

Business Wire

a month ago

New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know

Zacks

2 months ago

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know

Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas

Business Wire

2 months ago

Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Business Wire

2 months ago

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus

Business Wire

2 months ago

New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year

Business Wire

2 months ago

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year

DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms

Business Wire

2 months ago

DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms

Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL)

GuruFocus.com

3 months ago

Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL)

Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Business Wire

3 months ago

Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences to Participate in Upcoming Investor Conferences

Business Wire

3 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Castle Biosciences Second Quarter 2024 Earnings: Beats Expectations

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates

Zacks

4 months ago

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

4 months ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Business Wire

4 months ago

Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know

Zacks

4 months ago

Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know

Investors in Castle Biosciences (NASDAQ:CSTL) have unfortunately lost 71% over the last three years

Simply Wall St.

4 months ago

Investors in Castle Biosciences (NASDAQ:CSTL) have unfortunately lost 71% over the last three years

Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion

Zacks

4 months ago

Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion

Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma

Business Wire

4 months ago

Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma

5 Top Small Cap Stocks to Buy Now

Zacks

4 months ago

5 Top Small Cap Stocks to Buy Now

Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024

Business Wire

4 months ago

Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024

All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy

Zacks

4 months ago

All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy

Castle Biosciences Honored with Top Workplaces Awards

Business Wire

4 months ago

Castle Biosciences Honored with Top Workplaces Awards

Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test

Business Wire

5 months ago

Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

Business Wire

5 months ago

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?

Zacks

5 months ago

Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

5 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

5 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

5 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

5 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

5 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

5 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

5 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

5 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

Business Wire

6 months ago

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Business Wire

6 months ago

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?

Zacks

6 months ago

Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'

Zacks

6 months ago

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

Business Wire

6 months ago

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Business Wire

6 months ago

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"

Business Wire

6 months ago

Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"

MT Newswires

6 months ago

Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Business Wire

6 months ago

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Zacks

7 months ago

Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable

Zacks

7 months ago

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable

Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.

7 months ago

Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript

Insider Monkey

7 months ago

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Business Wire

7 months ago

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...

GuruFocus.com

7 months ago

Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Zacks

7 months ago

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Castle Biosciences Reports First Quarter 2024 Results

Business Wire

7 months ago

Castle Biosciences Reports First Quarter 2024 Results

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

Business Wire

7 months ago

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn

Simply Wall St.

7 months ago

We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Business Wire

7 months ago

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Business Wire

7 months ago

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Business Wire

7 months ago

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

What Makes Castle Bioscience (CSTL) a Prospective Investment?

Insider Monkey

8 months ago

What Makes Castle Bioscience (CSTL) a Prospective Investment?

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Business Wire

8 months ago

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire

8 months ago

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire

8 months ago

Castle Biosciences Announces Updates to its Board of Directors

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Business Wire

8 months ago

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Business Wire

8 months ago

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Share on Social Networks: